Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- FJPWA Opposes Harsher Changes in NHI Price Revision Rule: Mr Kojima
January 22, 2001
- ON THE MOVE
January 22, 2001
- JPMA Committee Calls For Deregulation to Allow Supply of Information Via Internet
January 22, 2001
- JMA to Clarify Details of Its Grand Healthcare Design
January 22, 2001
- MRs Should Take Cooperation between Medical Facilities into Account: Seminar
January 22, 2001
- Handicapped Persons to Be Given Opportunity to Become Doctors, Dentists, Nurses
January 22, 2001
- BUSINESS NEWS IN BRIEF -1-
January 22, 2001
- 2001 Meeting Schedule of the Japanese Association of Medical Sciences
January 22, 2001
- BUSINESS NEWS IN BRIEF -2-
January 22, 2001
- Celera Genomics Signs Contract with Univ. of Tokyo on Genome Database
January 22, 2001
- New Health Ministry's Budget Totals \18 Trillion, +4.5% Over FY2000
January 15, 2001
- Fukujin Becomes Hokuho Iyaku's Major Shareholder
January 15, 2001
- Glaxo Wellcome Changes Its Name to Glaxo SmithKline, Relocates Head Office
January 15, 2001
- Arimidex Approved as 1st Drug Based on Bridging Studies in Japan
January 15, 2001
- Dainippon Starts Full Operation of New PMS Information System
January 15, 2001
- BUSINESS NEWS IN BRIEF -1-
January 15, 2001
- Use of Overseas Data Recommended to Develop Pediatric Drugs
January 15, 2001
- Use New Technology to Meet Existing Needs in Healthcare: Mr Tanimura
January 15, 2001
- BUSINESS NEWS IN BRIEF -2-
January 15, 2001
- CPAC to Become Pharmaceutical Affairs and Food Sanitation Council
January 15, 2001
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…